Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | NQO1 | P15559 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | VKORC1 | Q9BQB6 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TOP1 | P11387 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106662 | 0.90 | ADORA3 (0.62) | ADORA3CYP2C9NQO1ALDH1A1VKORC1 | |
| SCHEMBL5103844 | 0.90 | NQO1 (0.72) | ADORA3CYP2C9NQO1ALDH1A1VKORC1 | |
| SCHEMBL5103329 | 0.88 | ADORA3 (0.60) | ADORA3CYP2C9NQO1ALDH1A1VKORC1 | |
| SCHEMBL5111769 | 0.88 | ADORA3 (0.62) | ADORA3CYP2C9NQO1ALDH1A1VKORC1 | |
| Ethyl Biscoumacetate SCHEMBL29359768 | 0.87 | ADORA3 (1.00) | ADORA3CYP2C9NQO1ALDH1A1VKORC1 | |
| Ethyl Biscoumacetate SCHEMBL42830 | 0.87 | ADORA3 (1.00) | ADORA3CYP2C9NQO1ALDH1A1VKORC1 | |
| SCHEMBL5100306 | 0.85 | CYP2C9 (0.71) | ADORA3CYP2C9NQO1ALDH1A1VKORC1 | |
| SCHEMBL5107024 | 0.82 | ADORA3 (0.86) | ADORA3CYP2C9NQO1ALDH1A1VKORC1 | |
| SCHEMBL14078678 | 0.81 | ADORA3 (0.70) | ADORA3CYP2C9NQO1ALDH1A1VKORC1 | |
| SCHEMBL8042698 | 0.81 | CYP2C9 (0.86) | ADORA3CYP2C9NQO1ALDH1A1VKORC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | DRUZGALA PASCAL | 2008-09-11 | — | — | US | claimed |
| US-7145020-B2 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS (US) | 2006-12-05 | — | — | US | claimed |
| EP-2161261-B1 | Materials and methods for treating coagulation disorders | ARMETHEON INC (US) | 2013-08-28 | — | — | EP | disclosed |
| CN-1950353-B | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS | 2011-06-01 | — | — | CN | disclosed |
| US-7932405-B2 | Halogenated ester derivatives of coumarins for the treatment of coagulation disorders | ARYX THERAPEUTICS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2161261-A1 | Materials and methods for treating coagulation disorders | Aryx Therapeutics (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7666902-B2 | 1,1,1,3,3,3-hexachloro-2-methylpropan-2-yl 4-((4-hydroxy-2-oxo-2H-chromen-3-yl)methyl)benzoate; side effect reduction over warfarin | ARYX THERAPEUTICS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1735296-B1 | MATERIALS AND METHODS FOR TREATING COAGULATION DISORDERS | ARYX THERAPEUTICS (US) | 2009-12-09 | — | — | EP | disclosed |
| US-20090082430-A1 | Materials and Methods for Treating Coagulation Disorders | ARYX THERAPEUTICS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | DRUZGALA PASCAL | 2008-09-11 | — | — | US | disclosed |
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | DRUZGALA PASCAL | 2008-09-11 | — | — | US | disclosed |
| US-20060287388-A1 | Materials and Methods for Treating Coagulation Disorders | ARYX THERAPEUTICS (US) | 2006-12-21 | — | — | US | disclosed |
| US-7145020-B2 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS (US) | 2006-12-05 | — | — | US | disclosed |
| US-20050245603-A1 | Materials and methods for treating coagulation disorders | ESPERO BIOPHARMA, INC. | 2005-11-03 | — | — | US | disclosed |
| US-6864279-B2 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS (US) | 2005-03-08 | — | — | US | disclosed |
| US-20040220258-A1 | Materials and methods for treating coagulation disorders | ESPERO BIOPHARMA, INC. | 2004-11-04 | — | — | US | disclosed |
| EP-1383756-A1 | COUMARIN DERIVATIVES TO BE USED AS ANTICOAGULANTS | Arxy Therapeutics (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030199573-A1 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS, INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2002085882-A1 | COUMARIN DERIVATIVES TO BE USED AS ANTICOAGULANTS | ARXY THERAPEUTICS (US) | 2002-10-31 | — | — | WO | disclosed |
| CN-1117291-A | 4-Hydroxy-pyran-2-one derivatives for the treatment of retroviral infections | UPJOHN CO (US) | 1996-02-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245603-A1 | Materials and methods for treating coagulation disorders | F12, F2, SERPINC1 | ADORA3 124/4885CYP2C9 553/4885NQO1 390/4885 |
| US-20030199573-A1 | Materials and methods for treating coagulation disorders | CES1, F2, CYP3A5 | ADORA3 2300/4885CYP2C9 24/4885NQO1 249/4885 |
| US-20060287388-A1 | Materials and Methods for Treating Coagulation Disorders | F12, F2, SERPINC1 | ADORA3 124/4885CYP2C9 553/4885NQO1 390/4885 |
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | CES1, F2, CYP3A5 | ADORA3 2300/4885CYP2C9 24/4885NQO1 249/4885 |
| US-20090082430-A1 | Materials and Methods for Treating Coagulation Disorders | F12, F2, SERPINC1 | ADORA3 124/4885CYP2C9 553/4885NQO1 390/4885 |
| US-20040220258-A1 | Materials and methods for treating coagulation disorders | CES1, F2, CYP3A5 | ADORA3 2300/4885CYP2C9 24/4885NQO1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.